The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy
Abstract
Currently, no effective and safe medicines are available to treat diabetic nephropathy (DN). Bardoxolone methyl (CDDO-Me) has displayed promising anti-DN activity as well as serious side effects in clinical trials, probably because the highly reactive α-cyano-α,β-unsaturated ketone (CUK) in ring A of CDDO-Me can covalently bind to thiol functionalities in many biomacromolecules. In this study, we designed and synthesized a γ-glutamyl transpeptidase (GGT)-based and CUK-modified derivative of CDDO-Me (2) to address this issue. 2 can be specifically cleaved by GGT, which is highly expressed in the kidney, to liberate CDDO-Me in situ. It should be noted that 2 exhibited anti-DN efficacy comparable to that of CDDO-Me with much less toxicity in cells and db/db mice, suggesting that its safety is better than CDDO-Me. Our findings not only reveal the therapeutic potential of 2 but also provide a strategy to optimize other synthetic molecules or natural products bearing a pharmacophore like CUK to achieve safer pharmaceutical drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“although they (and other agents that act via Nrf2) should be used with caution because too much Nrf2 activation can be deleterious89,95.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [95]
Citations
Cites
Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Self-citationPharmacology of oleanolic acid and ursolic acid
Liu, J. (1995) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(95)90032-2 · Cited by 1,429
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy
Navarro-González, J. F., Mora-Fernández, C., de Fuentes, M. M., & García-Pérez, J. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.51 · Cited by 1,072
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G. L., Chin, M., Christ-Schmidt, H., Goldsberry, A., Houser, M., Krauth, M., Lambers Heerspink, H. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306033 · Cited by 1,030
p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload
Sano, M., Minamino, T., Toko, H., Miyauchi, H., Orimo, M., Qin, Y., Akazawa, H., Tateno, K., Kayama, Y., Harada, M., et al. (2007) · Nature · doi:10.1038/nature05602 · Cited by 905
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Drug-induced mitochondrial dysfunction and cardiotoxicity
Varga, Z. V., Ferdinandy, P., Liaudet, L., & Pacher, P. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00554.2015 · Cited by 531
Diabetic kidney disease in the db/db mouse
Sharma, K., McCue, P., & Dunn, S. R. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00315.2002 · Cited by 521
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., & Taunton, J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.925 · Cited by 493
The impact of drug-induced QT interval prolongation on drug discovery and development
Fermini, B., & Fossa, A. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1108 · Cited by 492
Avosentan for Overt Diabetic Nephropathy
Mann, J. F. E., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S. J., Littke, T., & Viberti, G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060593 · Cited by 492
Noh, J., Kwon, B., Han, E., Park, M., Yang, W., Cho, W., Yoo, W., Khang, G., & Lee, D. (2015) · Nature Communications · doi:10.1038/ncomms7907 · Cited by 461
Modular Activation of Nuclear Factor-κB Transcriptional Programs in Human Diabetic Nephropathy
Schmid, H., Boucherot, A., Yasuda, Y., Henger, A., Brunner, B., Eichinger, F., Nitsche, A., Kiss, E., Bleich, M., Gröne, H.-J., et al. (2006) · Diabetes · doi:10.2337/db06-0477 · Cited by 419
Liby, K. T., & Sporn, M. B. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004846 · Cited by 405
Triterpenoids as new promising anticancer drugs
Petronelli, A., Pannitteri, G., & Testa, U. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328330fd90 · Cited by 381
Oxidative stress in early diabetic nephropathy: fueling the fire
Singh, D. K., Winocour, P., & Farrington, K. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.212 · Cited by 353
Sporn, M. B., Liby, K. T., Yore, M. M., Fu, L., Lopchuk, J. M., & Gribble, G. W. (2011) · Journal of Natural Products · doi:10.1021/np100826q · Cited by 312
Hydrogen Peroxide Inducible DNA Cross-Linking Agents: Targeted Anticancer Prodrugs
Kuang, Y., Balakrishnan, K., Gandhi, V., & Peng, X. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2073824 · Cited by 311
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
Gilbert, R. E., & Krum, H. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61402-1 · Cited by 293
Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO
Cleasby, A., Yon, J., Day, P. J., Richardson, C., Tickle, I. J., Williams, P. A., Callahan, J. F., Carr, R., Concha, N., Kerns, J. K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098896 · Cited by 258
Triterpenoid CDDO-Me Blocks the NF-κB Pathway by Direct Inhibition of IKKβ on Cys-179
Ahmad, R., Raina, D., Meyer, C., Kharbanda, S., & Kufe, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607160200 · Cited by 238
Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD
Pergola, P. E., Krauth, M., Huff, J. W., Ferguson, D. A., Ruiz, S., Meyer, C. J., & Warnock, D. G. (2011) · American Journal of Nephrology · doi:10.1159/000327599 · Cited by 233
Mouse models of diabetic nephropathy
Alpers, C. E., & Hudkins, K. L. (2011) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e3283451901 · Cited by 213
Histochemical Demonstration of Gamma-Glutamyl Transpeptidase
ALBERT, Z., ORLOWSKI, M., & SZEWCZUK, A. (1961) · Nature · doi:10.1038/191767a0 · Cited by 208
Amslinger, S. (2010) · ChemMedChem · doi:10.1002/cmdc.200900499 · Cited by 204
The protective effect of CDDO-Me on lipopolysaccharide-induced acute lung injury in mice
Chen, T., Mou, Y., Tan, J., Wei, L., Qiao, Y., Wei, T., Xiang, P., Peng, S., Zhang, Y., Huang, Z., et al. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.01.011 · Cited by 149
Self-citationShishodia, S., Sethi, G., Konopleva, M. Y., Andreeff, M., & Aggarwal, B. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2044 · Cited by 147
Liby, K. T., Royce, D. B., Williams, C. R., Risingsong, R., Yore, M. M., Honda, T., Gribble, G. W., Dmitrovsky, E., Sporn, T. A., & Sporn, M. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4534 · Cited by 146
Oakley, A. J., Rossjohn, J., Bello, M. L., Caccuri, A. M., Federici, G., & Parker, M. W. (1997) · Biochemistry · doi:10.1021/bi962316i · Cited by 134
gamma-Glutamyl dopa: a kidney-specific dopamine precursor.
Wilk, S., Mizoguchi, H., & Orłowski, M. (1978) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31317-0 · Cited by 118
CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes
Reisman, S. A., Buckley, D. B., Tanaka, Y., & Klaassen, C. D. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.12.024 · Cited by 114
Couch, R. D., Browning, R. G., Honda, T., Gribble, G. W., Wright, D. L., Sporn, M. B., & Anderson, A. C. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.03.031 · Cited by 110
Tate, S. S., & Ross, M. E. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40026-3 · Cited by 107
Proteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTOR
Yore, M. M., Kettenbach, A. N., Sporn, M. B., Gerber, S. A., & Liby, K. T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022862 · Cited by 106
Reversible Michael Additions: Covalent Inhibitors and Prodrugs
Johansson, M. H. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/13895575112091330 · Cited by 96
Rosengren, A., Vestberg, D., Svensson, A., Kosiborod, M., Clements, M. A., Rawshani, A., Pivodic, A., Guðbjörnsdóttir, S., & Lind, M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00292-2 · Cited by 91
Design of Self-Immolative Linkers for Tumour-Activated Prodrug Therapy
Tranoy‐Opalinski, I., Fernandes, A. E., Thomas, M., GESSON, J. ‐., & Papot, S. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008785133065 · Cited by 90
Gamma‐Glutamyl Transpeptidase Substrate Specificity and Catalytic Mechanism
Keillor, J. W., Castonguay, R., & Lherbet, C. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)01027-x · Cited by 80
Woods, J. R., Mo, H., Bieberich, A. A., Alavanja, T., & Colby, D. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201114t · Cited by 73
Ai, Y., Kang, F., Huang, Z., Xue, X., Lai, Y., Peng, S., Tian, J., & Zhang, Y. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5019302 · Cited by 71
Self-citationThe synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent
Vannini, N., Lorusso, G., Cammarota, R., Barberis, M. C. P., Noonan, D. M., Sporn, M. B., & Albini, A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0451 · Cited by 57
Samudio, I. J., Kurinna, S. M., Ruvolo, P. P., Korchin, B., Kantarjian, H. M., Beran, M., Dunner, K., Kondo, S., Andreeff, M., & Konopleva, M. Y. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0553 · Cited by 53
Worth, D., Harvey, J. N., Brown, J. J., & Lee, M. R. (1985) · Clinical Science · doi:10.1042/cs0690207 · Cited by 45
Ai, Y., Hu, Y., Kang, F., Lai, Y., Jia, Y., Huang, Z., Peng, S., Ji, H., Tian, J., & Zhang, Y. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5020023 · Cited by 38
Self-citationLampiasi, N., Azzolina, A., Umezawa, K., Montalto, G., McCubrey, J. A., & Cervello, M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.008 · Cited by 35
Bioactive Diterpenoid Containing a Reversible “Spring-Loaded” ( E,Z )-Dieneone Michael Acceptor
Gupta, P., Sharma, U., Schulz, T. C., Sherrer, E. S., McLean, A. B., Robins, A. J., & West, L. M. (2011) · Organic Letters · doi:10.1021/ol201443k · Cited by 24
Metabolism and vascular effects of gamma-L-glutamyl-L-dopa on the isolated rat kidney
Barthelmebs, M., Caillette, A., Ehrhardt, J. D., Velly, J., & Imbs, J. (1990) · Kidney International · doi:10.1038/ki.1990.131 · Cited by 24
Unsaturated Nitriles: Conjugate Addition−Silylation with Grignard Reagents
Fleming, F. F., Pu, Y., & Tercek, F. (1997) · The Journal of Organic Chemistry · doi:10.1021/jo9705430 · Cited by 24
Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease
Nogueira, C., Souto, S. B., Vinha, E., Braga, D. C., & Carvalho, D. M. (2013) · HORMONES · doi:10.14310/horm.2002.1436 · Cited by 21
Dong, Y., Ng, W. K., Surana, U., & Tan, R. B. H. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.01.013 · Cited by 18
Emerging drugs for managing kidney disease in patients with diabetes
Thomas, M. C. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.762356 · Cited by 10
Zhang, Q., Milliken, P. H., Kulczyńska‐Przybik, A., Slawin, A. M. Z., Gordon, A. R., Kirkby, N. S., Webb, D. J., Botting, N. P., & Megson, I. L. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400146r · Cited by 8
Renal Metabolism and Effects of the Glutamyl Derivatives of l -Dopa and 5-Hydroxytryptophan in Man
Wa, T. C. L. K., Freestone, S. H., Samson, R. R., Johnston, N. R., & Lee, M. R. (1996) · Clinical Science · doi:10.1042/cs0910177 · Cited by 7
Cited by
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Rayego-Mateos, S., Morgado-Pascual, J. L., Opazo-Ríos, L., Guerrero-Hue, M., García-Caballero, C., Vázquez-Carballo, C., Mas, S., Sanz, A. B., Herencia, C., Mezzano, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113798 · Cited by 334
Ergothioneine – a diet‐derived antioxidant with therapeutic potential
Halliwell, B., Cheah, I. K., & Tang, R. M. Y. (2018) · FEBS Letters · doi:10.1002/1873-3468.13123 · Cited by 305
Mini-Review: Oxidative stress, redox stress or redox success?
Gutteridge, J. M. C., & Halliwell, B. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.045 · Cited by 227
The role of natural products in revealing NRF2 function
Zhang, D. D., & Chapman, E. (2020) · Natural Product Reports · doi:10.1039/c9np00061e · Cited by 124
Metadata
- Authors
- Huang, Z., Mou, Y., Xu, X., Zhao, D., Lai, Y., Xu, Y., Chen, C., Li, P., Peng, S., Tian, J., & Zhang, Y.
- Affiliations
- University of California, Los Angeles (US)
- Crystal Pharmatech Co., Ltd., Suzhou 215123, P.R. China
- Corresponding author
- Huang, Zhangjian
- Xu, Xiaojun
- Zhang, Yihua
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-10-19
- Volume
- 60
- Issue
- 21
- Pages
- 8847-8857
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2763829705
- Cited by
- 40
- References
- 57
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 5 · 2021: 9 · 2020: 8 · 2019: 5 · 2018: 3
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Program for New Century Excellent Talents in University (NCET-13-1033)
- National Natural Science Foundation of China (21372261, 21472244, 81673305)
- Jiangsu Province (BK20160033)
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- bardoxolone methyl, diabetic nephropathy, gamma-glutamyl transferase, prodrugs, drug safety, thiol reactivity, db/db mice, drug design
- MeSH terms
- Animals, Diabetic Nephropathies, Drug Therapy, gamma-Glutamyltransferase, Humans, Kidney, Oleanolic Acid, Mice, Rats, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.